Needham Reiterates Buy on Biogen, Maintains $321 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia reiterates a Buy rating on Biogen (NASDAQ:BIIB) and maintains a $321 price target.
June 12, 2023 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Biogen and maintains a $321 price target.
The news directly mentions Biogen and the analyst's Buy rating and price target. This reaffirmation of the Buy rating by Needham analyst Ami Fadia could positively impact the stock price in the short term as it signals confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100